

# *cpt*<sup>®</sup> Assistant

Official source for CPT coding guidance

## SPECIAL EDITION: May Update

### New COVID-19 Vaccine Codes: May Update

Current Procedural Terminology (CPT<sup>®</sup>) codes for a new vaccine product from Novavax and its administration have been added to previously established vaccine codes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]). The CPT Editorial Panel has approved the latest vaccine product code, which will become effective upon receiving the Emergency Use Authorization (EUA) or approval from the Food and Drug Administration (FDA).

In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>) that features timely updates of the CPT Editorial Panel actions.

The most recent COVID-19 update was in the *CPT<sup>®</sup> Assistant Special Edition: January Update (2021)* in which vaccine product code 91303 (Janssen, single-dose vaccine) was established with its corresponding administration code (0031A). This article introduces the Novavax two-dose vaccine code (91304) and its associated administration codes (0041A, 0042A).

It also provides guidance on the appropriate use of these new codes.

### Immunization Administration for Vaccines/Toxoids

**90460** Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered

**+90461** each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)

(Use 90460 for each vaccine administered. For vaccines with multiple components [combination vaccines], report 90460 in conjunction with 90461 for each additional component in a given vaccine)

*continued on next page*

►(Do not report 90460, 90461 in conjunction with 91300, 91301, 91302, 91303, 91304, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90749, 90756 are administered at the same encounter)◀

●0041A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose

●0042A second dose

►(Report 0041A, 0042A for the administration of vaccine 91304)◀

## Vaccines, Toxoids

#✓●91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use

►(Report 91304 with administration codes 0041A, 0042A)◀

Previously established COVID-19 vaccine code 91303 describes the use of a single-dose vaccine that uses recombinant, replication-incompetent human adenovirus type 26 (Ad26) as the vector. This vaccine has a single-dose regimen that requires a single administration code (0031A).

However, the new Novavax vaccine product (91304) is different in that it is a two-dose vaccine that requires two administration codes (0041A, 0042A). The purified protein used in this vaccine is “encoded by the genetic sequence of the SARS-CoV-2 spike (S) protein and is produced in insect cells.”<sup>1</sup> The vaccine, which is described in code 91304 has a dosage regimen of 5 mcg/0.5mL, for intramuscular use.

To accommodate the new coding structure, a new Appendix Q has been added to the CPT code set. Appendix Q details the vaccine codes, their associated vaccine administration code(s), the vaccine manufacturers and names, the National Drug Code (NDC) labeler product ID, and dosing intervals. The new Novavax vaccine product code (91304) and its respective administration codes (0041A, 0042A) have also been added to Appendix Q.

Additional details on the new vaccine coding structure and other pertinent information provided in multiple special editions of the *CPT® Assistant* for COVID-19 guidance are available at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.

The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

### Clinical Example (91304)

A 33-year-old individual seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

### Description of Procedure (91304)

The physician or other qualified health care professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose schedule in the administration code for the SARS-CoV-2 vaccine.

### Clinical Example (0041A)

A 33-year-old individual seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

### Description of Procedure (0041A)

The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the first dose of the COVID-19 vaccine by intramuscular

injection in the upper arm. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

## Clinical Example (0042A)

A 33-year-old individual seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

## Description of Procedure (0042A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk

of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the second dose of the COVID-19 vaccine by intramuscular injection in the upper arm. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

## Reference

1. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. News Release. Novavax. January 28, 2021. Accessed March 31, 2021. <https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3#:~:text=NvX%2DCoV2373%20contains%20a%20full,is%20produced%20in%20insect%20cells>.

AMA Plaza  
330 North Wabash Avenue  
Chicago, Illinois 60611-5885

NON-PROFIT ORG  
U.S. POSTAGE  
**PAID**  
AMERICAN MEDICAL  
ASSOCIATION



# *cpt*<sup>®</sup> Assistant

Official source for CPT coding guidance

## AMA Staff

**Leslie W. Prellwitz, MBA, CCS, CCS-P**, Managing Editor  
**Rejina Young**, Editorial Assistant

### Contributing Staff

Samantha Ashley; Jennifer Bell; Andrei Besleaga;  
Karen O'Hara; Leslie W. Prellwitz; Keisha Sutton-Asaya;  
Donna Tyler; Arletrice Watkins; Rejina Young

### Development and Production Staff

Mary Ann Albanese; Elizabeth Goodman Duke;  
Lisa Chin-Johnson; Elizabeth Kennedy

## Order Information

1 year (12 issues)  
AMA Members\* .....\$187.50      Nonmembers.....\$250.00

### Orders:

[ama-assn.org/subscriptions](http://ama-assn.org/subscriptions)

\*To receive the member price, please provide the member's number.

To change address information, please call AMA's Customer Services Department at (800) 621-8335.

Notification of change of address must be made at least six weeks in advance.

AMA website: [www.ama-assn.org](http://www.ama-assn.org)

### Mailing address:

CPT Assistant  
AMA Plaza  
330 North Wabash Avenue  
Chicago, IL 60611-5885

The *CPT<sup>®</sup> Assistant Special Edition* information is designed to provide accurate, up-to-date coding information. We continue to make every reasonable effort to ensure the accuracy of the material presented. However, this publication does not replace the CPT<sup>®</sup> codebook; it serves only as a guide.

©2021. American Medical Association. All rights reserved. No part of this publication may be reproduced in any form without prior written permission of the publisher. CPT<sup>®</sup> is a registered trademark of the American Medical Association.